Wuhan Hiteck Biological Pharma Co Ltd (300683) — Tangible Net Worth Ratio
Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Tangible Net Worth Ratio of 88.4% as of September 2025. This metric is calculated by deducting intangible assets (CN¥260.23 Million) from net assets (CN¥2.24 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Wuhan Hiteck Biological Pharma Co Ltd (300683) shareholders funds for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Wuhan Hiteck Biological Pharma Co Ltd Tangible Net Worth Ratio (2013–2024)
This chart shows how Wuhan Hiteck Biological Pharma Co Ltd's Tangible Net Worth Ratio has changed across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 88.4%, reflecting net assets of CN¥2.24 Billion with intangible assets of CN¥260.23 Million CNY. Also explore 300683 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Wuhan Hiteck Biological Pharma Co Ltd (300683) total market value.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 88.4% | CN¥2.41 Billion | CN¥279.24 Million | CN¥2.94 Billion | ▲ +0.4 pp |
| 2023 | 88.0% | CN¥2.50 Billion | CN¥298.66 Million | CN¥2.97 Billion | ▼ -8.1 pp |
| 2022 | 96.1% | CN¥2.34 Billion | CN¥91.38 Million | CN¥2.71 Billion | ▼ -0.1 pp |
| 2021 | 96.2% | CN¥2.34 Billion | CN¥90.19 Million | CN¥2.70 Billion | ▲ +1.7 pp |
| 2020 | 94.5% | CN¥1.72 Billion | CN¥95.00 Million | CN¥2.19 Billion | ▼ -1.9 pp |
| 2019 | 96.4% | CN¥1.76 Billion | CN¥63.79 Million | CN¥2.17 Billion | ▲ +0.2 pp |
| 2018 | 96.1% | CN¥1.71 Billion | CN¥66.11 Million | CN¥2.16 Billion | ▼ -2.8 pp |
| 2017 | 98.9% | CN¥1.64 Billion | CN¥18.19 Million | CN¥1.91 Billion | ▲ +1.6 pp |
| 2016 | 97.3% | CN¥703.35 Million | CN¥18.78 Million | CN¥1.04 Billion | ▲ +0.6 pp |
| 2015 | 96.7% | CN¥596.76 Million | CN¥19.51 Million | CN¥872.49 Million | ▲ +0.5 pp |
| 2014 | 96.2% | CN¥536.59 Million | CN¥20.31 Million | CN¥801.37 Million | ▲ +4.5 pp |
| 2013 | 91.7% | CN¥254.64 Million | CN¥21.07 Million | CN¥441.07 Million | — |